NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I’d only expect a slight (inconsequential) difference for intent for near total gross resection, because other trials typically only include accessible tumors.

Remember, the easy tumors to remove are not the ones DCVax-l works best on. Instead, mesenchymal tumors are more infiltrative and tend to jut out in various places. This is probably why you still see many partial resections in the DCVax-l trial.

Whereas the Survax trial takes an MRI three days after surgery and excludes anything that isn’t proven to be a total or very near total resection. That just seems like a blatant way to increase survival, and therefore requires a placebo controlled trial, because there aren’t external arm control possibilities.